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Abstract
Background: Selective prophylactic decontamination of the digestive tract is a strategy for the prevention of
secondary nosocomial infection in patients with avian influenza virus subtype H7N9 infection. Our aim was to
summarize the effectiveness of these therapies in re-establishing a stable and diverse microbial community, and
reducing secondary infections.
Methods: Comprehensive therapies were dependent on the individual clinical situation of subjects, and were
divided into antiviral treatment, microbiota-targeted therapies, including pro- or pre-biotics and antibiotic usage,
and immunotherapy. Quantitative polymerase chain reaction and denaturing gradient gel electrophoresis (DGGE)
were used for real-time monitoring of the predominant intestinal microbiome during treatment. Clinical information
about secondary infection was confirmed by analyzing pathogens isolated from clinical specimens.
Results: Different antibiotics had similar effects on the gut microbiome, with a marked decrease and slow recovery
of the Bifidobacterium population. Interestingly, most fecal microbial DGGE profiles showed the relative stability of
communities under the continual suppression of the same antibiotics, and significant changes when new
antibiotics were introduced. Moreover, we found no marked increase in C-reactive protein, and no cases of
bacteremia or pneumonia, caused by probiotic use in the patients, which confirmed that the probiotics used in this
study were safe for use in patients with H7N9 infection. Approximately 72% of those who subsequently suffered
exogenous respiratory infection by Candida species or multidrug-resistant Acinetobacter baumannii and Klebsiella
pneumoniae were older than 60 years. The combination of probiotics and prebiotics with antibiotics seemed to fail
in these patients.
Conclusions: Elderly patients infected with the influenza A (H7N9) virus are considered a high-risk group for
developing secondary bacterial infection. Microbiota restoration treatment reduced the incidence of enterogenous
secondary infection, but not exogenous respiratory infection. The prophylactic effects of microbiota restoration
strategies for secondary infection were unsatisfactory in elderly and critically ill patients.
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Background
Forty cases of confirmed avian influenza virus subtype
H7N9 infection were treated at the First Affiliated
Hospital of Zhejiang University (China) during
March–April 2013. Most of the patients were critic-
ally ill and required admission to an intensive care
unit [1], wheretreatment can be divided into antiviral
treatment, microbiota-targeted therapies, and im-
munotherapy. Secondary invasive bacterial infections
associated with H7N9 infection can cause severe and
fatal complications, and appropriate empirical anti-
biotic treatment for hospital-acquired bacterial infec-
tions is required. The human gut harbors a complex
microbiome that plays a fundamental role in host
health through its involvement in nutritional, im-
munological, and physiological functions [2]. Recipro-
cal interactions between intestinal microbiota and the
human mucosal immune response influence the
development of disease through activation of innate
and adaptive immune responses [3]. Antibiotics have
a profound disruptive effect on the intestinal micro-
biome [4], which is frequently accompanied by
colonization of pathogenic microbes and dysbiosis of
the host immune system, contributing to the develop-
ment of potentially serious diseases [5,6]. Therefore,
microbiota restoration strategies, which allow benefi-
cial bacteria to thrive, eliminate colonization by op-
portunistic pathogens, and enhance resistance to
intestinal colonization, are required for treatment of
H7N9 infection. Intestinal colonization resistance is
defined as the resistance to colonization by ingested
bacteria or inhibition of overgrowth of resident
bacteria normally present at low levels within the in-
testinal tract [7]. Probiotics and prebiotics have a
beneficial effect on regeneration and restoration of
microbiome homeostasis [8]. Additionally, more re-
cent data show that probiotics can modulate host
immunoregulation, alleviate intestinal inflammation,
normalize gut mucosal dysfunction, and downregulate
hypersensitivity reactions through control of proin-
flammatory and anti-inflammatory cytokines [9]. The-
oretically, targeted microbiota-regulating treatment
could prevent or alleviate the complications of H7N9
infection.
CBM588 (Clostridium butyricum 588 strain MIYA-BM
tablets; Miyarisan Pharmaceutical, Tokyo, Japan) pre-
vents antibiotic-associated diarrhea [10] and has anti-
inflammatory effects in the colon as a result of butyric
acid production [11]. We retrospectively assessed the ef-
fects of microbiota restoration strategies on restoring
intestinal homeostasis under antibiotic exposure, and
on reducing the risk of secondary infection, by real-time
monitoring of the shift in predominant intestinal bac-
teria using quantitative polymerase chain reaction
(qPCR) and PCR-based denaturing gradient gel electro-
phoresis (PCR-DGGE).
Methods
Patients and stool specimen sampling
The study was conducted between 1 April and 10 May
2013 in the First Affiliated Hospital, College of Medi-
cine of Zhejiang University, China. Approval for the col-
lection of patient stool samples was obtained from the
ethical board of the hospital. All patients voluntarily
joined the study and gave their informed consent. We
prospectively studied all consecutive, nonselected inpa-
tients who had episodes of influenza virus H7N9 infec-
tion. Patients were diagnosed according to the criteria
of the Centers for Disease Control, USA, in 2013 [12].
Stool samples were collected daily, and intestinal micro-
ecology was investigated in all specimens. Patients were
excluded if they provided fewer than four stool speci-
mens during the follow-up period. The follow-up for
each patient ended once their major method of feeding
changed, for example when patients that had been fed
using a nasogastric tube graduated to autonomous feed-
ing. Fecal samples were collected in sterile bags, refrig-
erated, and immediately taken to the laboratory where
they were aliquoted into 200-mg samples, frozen in li-
quid nitrogen, and stored at −75°C. Twenty-five patients
completed sampling, and a total of 205 specimens were
subject to qPCR and DGGE analysis. Eleven of these pa-
tients had secondary infection, of which, eight patients
were over 60 years of age. Patient characteristics were
collected from medical records and are in shown
Table 1. Patients were classified into five groups accord-
ing to microbiota-targeted treatment: Group A, two pa-
tients without any microbiota-targeted treatment during
follow-up; Group B, one patient with one antibiotic
only; Group C, six patients with probiotic only; Group
D, eight patients with one antibiotic and one probiotic;
and Group E, eight patients with two or more antibi-
otics and probiotics or prebiotics. Groups A–C had mild
disease and could feed independently, whereas Groups
D and E were critically ill and required nasogastric feed-
ing. Twenty-five healthy age- and sex-matched controls
(Table 1) were enrolled and provided only one stool
sample. The participants did not have any organic dis-
eases, none withdrew or were omitted from the study,
and none received antibiotics, probiotics, or prebiotics
during the sampling period.
DNA extraction
DNA was extracted from the feces and bacterial precipi-
tates using a Qiagen Stool Kit (Qiagen, Hilden, Germany)
with a modified protocol for cell lysis [13]. DNA integrity
was confirmed by agarose gel electrophoresis and ultravio-
let photography with ethidium bromide staining.
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Qualitative and quantitative PCR to detect predominant
intestinal bacterial population
Primers used were described in an earlier study [13]
(Table 2). All oligonucleotide primers were synthesized by
Takara (Dalian, China). Quantitative PCR was performed
using a ViiA 7 Real-Time PCR System (Applied Biosystems,
Foster City, CA, USA). Amplification reactions contained
10 μl of SYBR Green PCR Master Mix (Applied Biosys-
tems, Warrington, UK), 300 nM each primer, and 300 ng of
the respective crude template DNA or 1 μL of water (nega-
tive control) in a final volume of 20 μL. Each reaction was
performed in duplicate, and a ΔC (t) < 0.5 between dupli-
cates was required. Amplifications were performed with the
following temperature profiles: one cycle at 95°C for 3 min,
followed by 40 cycles of 95°C for 30 s, annealing for 40 s,
and 72°C for 30 s. Fluorescence was measured at 80°C for
10 s after the extension phase of each cycle to avoid inter-
ference from primer dimers, secondary structure, or
Table 1 Characteristics of all subjects andusage of microbiota-targeted agents in secondary infection and
non-secondary infection groups of H7N9 patients
Characteristics Secondary infection group Non-secondary infection group Healthy controls
(n = 11) (n = 14) (n = 25)
Median age (years) 64.5 48 58
Male:female (n) 9:2 8:6 17:8
Median hospital stay (days) 21.5 13 −a
Primary blood parameters at first follow-up:
Mean WBC (SD, 109cells per liter) 8.0 (3.5) 4.6 (3.3) 5.7 (1.3)
Mean CRP (SD, mg per liter) 61.7 (72.3) 42.8 (53.2) −
ALT median (25th–75th percentile, units per liter) 38 (25–50) 44 (19.5–114) 16 (12.5–21)
Antimicrobial usage: −
Cephalosporins (n) 7 9 −
Carbapenems (n) 6 1 −
β-Lactamase inhibitors and cephalosporins (n) 4 3 −
β-Lactamase inhibitors and penicillins (n) 9 5 −
Quinolones (n) 10 8 −
Macrolides (n) 4 1 −
Vancomycin (n) 5 0 −
Tigecycline (n) 4 0 −
Oxazolidinones (n) 3 0 −
Phosphonomycin (n) 1 1 −
Antifungalagents (n) 1 0 −
Micro-ecological-targeted agents −
CBM588 (n) 9 11 −
Bacillussubtilis- and E. faecium-coated enteric capsules (n) 1 1 −
Lactulose (n) 4 0 −
Infection with −
Canidia (n) 7 0 −
Klebsiella pneumoniae, n 6 0 −
Acinetobacter baumanii (n) 5 0 −
Pseudomonas (n) 5 0 −
Flavobacterium indologenes (n) 1 0 −
Staphylococcus (n) 2 0 −
Infections with mixed culture (n) 7 0 −
Diarrhea (n) 3 0 −
Abbreviations: WBC white blood cell, SD standard deviation, CRP C-reactive Protein, ALT alanine aminotransferase, CBM588, Clostridium butyricum 588 strain
MIYA-BM tablets.
aNot applicable.
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spurious priming. A final extension step of 72°C for 5 min
was performed. The annealing and plate-reading tempera-
tures for each primer pair are shown in Table 2. Following
amplification, melting temperature analysis of PCR
products was performed to determine the specificity of the
PCR. The melting curves were obtained by slow heating at
0.1°C/s from 65°C to 95°C, with continuous fluorescence
measurement.
The copy number of rDNA operons of targeted bacteria
in crude DNA templates was determined by comparison
with serially-diluted plasmid DNA standards run on the
same plate. The plasmid DNA standards were made from
known concentrations of plasmid DNA that contained the
respective amplicon for each set of primers, according to
Bartosch et al. [14]. Determination of the detection limit of
the assays was performed as described previously [15].
PCR amplification of the 16S rDNA V3 region
The V3 variable region of 16S rDNA was amplified using a
hot-start touchdown protocol with primers specific for con-
served regions of the 16S rRNA gene [16]. The reaction
mixture contained 800 ng of genomic DNA, 25 pmol of
each primer, 0.2 μM dNTPs, 1 × Ex Taq buffer, and 2.5 U of
Ex Taq polymerase (Takara). The final volume of the reac-
tion mixture was adjusted to 50 μL with sterile deionized
water. To minimize heteroduplex formation, five-cycle
reconditioning PCR was conducted using 5 μL of amplifica-
tion mixtures in fresh reaction mixture, as previously
described [17]. Thermal cycling was performed in a TPro-
fessional Thermocycler (Biometra, Göttingen, Germany).
Concentrations were measured using a NanoDrop ND-
1000 spectrophotometer (NanoDrop Technologies,
Wilmington, DE, USA, USA).
Denaturing gradient gel electrophoresis profiling
Parallel DGGE analysis was performed using the D-
Code universal mutation detection system apparatus
(Bio-Rad, Hercules, CA, USA) with 16 cm × 18 cm ×
1.5 mm gels. Sequence-specific separation of the PCR
fragments was obtained in 8% (wt/vol) polyacrylamide
(acrylamide-N, N’-bisacrylamide, 37.5:1 (wt/vol)) gels in
1 × TAE buffer (40 mM Tris, 20 mM glacial acetic acid,
1 mM EDTA, pH 8.0). Denaturing gels contained a 35–
75% gradient of urea and formamide, increasing in the
direction of electrophoresis. A 100% denaturing solution
contained 40% (vol/vol) formamide and 7 M urea. PCR
fragments (20 μL) were loaded onto gels and electro-
phoresis was conducted at a constant voltage of 70 V
and a temperature of 60°C for approximately 16 h. Fol-
lowing electrophoresis, gels were stained with SYBR
green I (Sigma-Aldrich, Castle Hill, Australia) and
photographed. Each DGGE gel included a standard ref-
erence (a randomly selected sample) in the middle and
at both ends for digital gel normalization, and to allow
comparison between gels.
DGGE profiles were digitally processed using BioNu-
merics software version 6.01 (Applied Maths, St-
Martens-Latem, Belgium) following the manufacturer’s
instructions. All profiles were compared using the band-
matching tool, and uncertain bands were included in the
position tolerance settings. Bands were allocated accord-
ing to the parameters of Joossens et al. [18]. Principal
components analysis (PCA) analysis and DGGE Bands
Sequencing were performed according to a previous
study [19].
Results
Retrospective analysis of microbiota-targeted treatment
and secondary infection
Early clinical experience with influenza virus H7N9 therapy
showed that patients often developed acute exacerbation
with bacterial superinfection. These serious complications
could sometimes be fatal. Prophylactic selective decontam-
ination of the digestive tract is suggested for increased
Table 2 Primers used in this study
Target group Sequence (5′–3′) Annealing temperature (°C)
Faecalibacterium prausnitzii GATGGCCTCGCGTCCGATTAG 58
CCGAAGACCTTCTTCCTCC
Bifidobacterium genus GGGTGGTAATGCCGGATG 59
TAAGCCATGGACTTTCACACC
Lactic acid bacteria AGCAGTAGGGAATCTTCCA 58
ATTYCACCGCTACACATG




Bacteroides-Prevotella group GAAGGTCCCCCACATTG 56
CAATCGGAGTTCTTCGTG
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survival of critically ill patients with H7N9 pneumonia.
Therefore, all patients in our study received different
broad-spectrum antibiotics in their district hospitals prior
to transfer (Table 1 and Figure 1) to remove any pathogenic
microorganisms. Most patients also received prophylactic
selective decontamination of the digestive tract during
the follow-up period. The antibiotics used in these pa-
tients were classified into nine groups according to
Figure 1 Real-time monitoring of the changes in six predominant bacterial populations in 1 μg of fecal microbial DNA in 25 patients. X
axis, course of the treatment; Y axis, copies of 16 s rDNA operon from targeted bacteria in 1 μg of fecal microbial DNA. Patient age is given
in brackets.
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molecular structure: cephalosporins (cefuroxime, cefoxi-
tin, cefmetazole, ceftazidime, cefotaxime, ceftriaxone, cef-
dinir, ceftizoxime, and cefepime), carbapenems (imipenem
and meropenem), β-lactam and β-lactamase inhibitors
(cefoperazone sodium and sulbactam sodium, piperacillin-
tazobactam, piperacillin sodium, and sulbactam sodium),
quinolones (moxifloxacin, ciprofloxacin, and levofloxacin),
macrolides (azithromycin and roxithromycin), vancomycin,
tigecycline, oxazolidinones (linezolid), phosphonomycin, and
antifungal agents (fluconazole and caspofungin). Probiotics,
including Clostrium butyricum-, Bacillus subtilis-, and En-
terococcus faecium-coated enteric capsules, and prebiotics,
such as lactulose, were used in most patients in consider-
ation of impaired intestinal colonization resistance and dis-
turbance of microbiota caused by the broad-spectrum
antimicrobial agents. Probiotic compounds were adminis-
tered as two tablets, three times per day (containing
~107 cfu/tablet for CBM588 and 108 cfu for B. subtilis and
E. faecium capsules). All microbiota-targeted agents were
taken as advised, and administered by an expert team ac-
cording to patient health status, the targeted disease, and
the recipient’s perceived risks and willingness.
Eleven patients (C5, D1, D3, D6, E1, E2, and E4–E8)
acquired secondary bacterial infections during their stay
in the intensive care unit for treatment of critical pneu-
monia. Eight of the eleven patients (72%) were older
than 60 years of age. Pathogens were isolated from their
clinical specimens. Six samples contained Klebsiella
pneumoniae (isolated from sputum), seven had Candida
species (isolated from sputum), five had Acinetobacter
baumanii (isolated from sputum), five had Pseudomonas
species (isolated from sputum), two had Staphylococcus
species (isolated from blood), and one had Flavobacter-
ium indologenes (isolated from blood). Seven had mixed
bacterial infections. Three patients from group E suf-
fered from antibiotic-associated diarrhea caused by Clos-
tridium difficile, which was cultured from stool samples.
We also monitored the real time concentration of C-
reactive protein (CRP), an early indicator of infection or
inflammation, in the blood of each patient. Results
showed that CRP tended to decrease in most H7N9 pa-
tients, particularly those without secondary infections
(Figure 2), which suggested that the probiotics used were
safe and did not cause an inflammatory state.
Figure 2 The concentrations of C-reactive protein (CRP) in blood (mg/L). A, Patients without secondary infection; B, patients with
secondary infections.
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Intestinal Bifidobacterium/Enterobacteriaceae ratio in
patients with H7N9 infection
All subjects were assessed for their intestinal Bifidobacter-
ium/Enterobacteriaceae (B/E) ratio in the total fecal micro-
bial DNA (Figure 3). B/E ratios of most healthy controls
were ≥1, except for four individuals aged ≥80 years (red tri-
angles in Figure 3) who had ratios < 1. In contrast, the ra-
tios of all patients were < 1, and most were even smaller
than in the elderly healthy controls.
Real-time monitoring of the predominant intestinal
microbiome
The quantification data of six predominant intestinal bac-
teria, Bifidobacterium, Enterobacteriaceae, Bacteroides-Pre-
votella group, Faecalibacterium prausnitzii, Enterococcus
faecalis, and lactic acid bacteria, were expressed as log10
16S rRNA gene copies in 1 μg fecal DNA. The levels of
these bacteria in healthy controls are shown in Figure 4.
Two patients, A1 and A2, only received antiviral treat-
ment at the follow-up stage, and antimicrobial treatment
in the early stage had significantly decreased the Bifido-
bacterium population (A1 and A2 in Figure 1). The in-
fluence of antibiotics on fecal bacteria was clearly
demonstrated in Patient B1, who had a marked decrease
in the six bacterial groups during a 5-day period of anti-
biotic treatment in the follow-up period (B1 in Figure 1).
The levels of these populations largely rebounded after
antibiotic treatment ended. Notably, this patient had an
increase in Enterobacteriaceae when taking piperacillin
sodium and sulbactam sodium, which suggested an in-
crease in resistant strains that are present in small num-
bers in the healthy intestinal tract. Patients C1–C6
received microbiota restoration therapies (C1–C6 in
Figure 1) without any antibiotics after enrollment, and
the population sizes of the six bacterial groups increased.
However, the populations of Bifidobacterium, F. praus-
nitzii, and lactic acid bacteria showed slight variation in
some cases. In particular, the six bacterial groups were
relatively stable in Patient C5, who received B. subtilis-
and E. faecium-coated enteric capsules; however, Can-
dida albicans was isolated from the sputum during
follow-up. Bacillus subtilis and E. faecium capsules re-
placed CBM588 tablets for 2 days in Patient C6, and the
six bacterial populations did not show substantial fluctu-
ations at the termination of probiotic treatment. Data
from eight patients in Group D who received one type
of antibiotic and CBM588 tablets showed that CBM588
decreased the impact of the antibiotics, and increased
the bacterial populationduring the period of continual
suppression of the same antibiotic (D1–D8 in Figure 1).
Additionally, the Bifidobacterium population generally
trended upward in most patients in Group D. For critic-
ally ill patients in Group E (E1–E8 in Figure 1), the pop-
ulations of the six bacterial groups fell to their lowest
levels and then began to rebound. Most patients in
Group E (7/8) had secondary infection and diarrhea dur-
ing the follow-up period.
Figure 5 shows the predominant intestinal microbiome
profiles of representatives of each group. The predomin-
ant intestinal microbiome of control subjects was more
evenly distributed, with higher species richness, than
that of patients. The predominant bands in the profiles
of B1 and A1 were distributed in the region where the
denaturant concentrations had a range of 37–57%, but
those dosed with C. butyricum for microbiota restor-
ation therapy (E3, D6, and C6 in the early phase) were
Figure 3 Intestinal B/E ratio in patients with influenza virus H7N9 infection and healthy age- and sex-matched controls. Ratios in most
patients were < 1. Triangles, healthy controls; diamonds, patients. Red symbols denote ≥80 years of age.
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distributed in the 57–70% region, which revealed that C.
butyricum might be involved in the recovery of bacteria
with high GC% in the V3 region of 16S rDNA. Con-
versely, the profile of C5 indicated that B. subtilis- and
E. faecium-coated enteric capsules might contribute to
the restoration of the entire fecal microbiota. In particu-
lar, for C6, the most predominant bands were distributed
in the 57–70% region in the early stages with C. butyri-
cum treatment, but were distributed evenly throughout
the entire gels when CBM588 was replaced by B. subtilis
and E. faecium capsules in the middle stage. Further-
more, the profiles of most patients during the follow-up
periods showed relative stability under the continual
suppression by the same antibiotics. In contrast, the
fecal DGGE profiles of E3 and E8 changed dramatically
when new antibacterial agents were introduced during
the microbiota restoration therapy.
PCA analysis of DGGE profiles of all patients showed
that the predominant intestinal microbiome of groups D
and E differed from groups A, B, and C (Figure 6).
Discussion
The gastrointestinal tract harbors more than 400 bacter-
ial species, each having a specific niche and playing im-
portant roles in human health and disease [20].
Although it is difficult to define the normal intestinal
microbiota, there is much evidence suggesting that the
balance of beneficial and harmful bacteria (including op-
portunistic pathogens) is disturbed in many disease
states [21-23]. Analysis of the fecal microbiota of healthy
controls using DGGE in this study revealed that healthy
gut microbiota was characterized by a relatively even
distribution and high species richness and diversity.
Most patients with influenza virus H7N9 infection had
already received antibiotics in the early stages of the dis-
ease, and some of them had received repeated antibiotic
therapy for secondary infections or prophylaxis against
healthcare-associated infections during the microbiota
restoration treatment period. In general, the more critic-
ally ill the patients were, the more antibiotics were used.
Much evidence suggests that antibiotics may cause a
profound imbalance within the intestinal microbiota [5]
and lead to complications. Therefore, administering
beneficial intestinal bacteria during selective decontam-
ination of the intestinal microbiome was recommended
by the therapy group in the present study. We moni-
tored the populations of the six predominant intestinal
bacterial groups, including three potential pathogens
(Enterobacteriaceae, Bacteroides-Prevotella group, and E.
faecalis), and three beneficial bacteria (Bifidobacterium
species, F. prausnitzii, and lactic acid bacteria). The B/E
values in this study revealed most young and elderly
adult patients with H7N9 infection had imbalances be-
tween Bifidobacterium and Enterobacteriaceae. The dis-
equilibrium could be caused by many factors, such as
the aging process, influenza virus infection, antibiotics,
and anorexia. Our results showed that Bifidobacterium
was most sensitive to antibioticsuppressionand recov-
ered poorly, even without antibiotic intervention. Add-
itionally, the increasing antimicrobial drug resistance
among Enterobacteriaceae [24] may largely account for
the disequilibrium. Bifidobacterium inhibits the growth
of various pathogens by several mechanisms, including
production of antimicrobial agents and short-chain fatty
acids, and competitive exclusion [25,26]. Thus, these
species play an important role in preventing colonization
of the intestine by pathogens. Furthermore, the Bifido-
bacterium population was often higher than or equal to
Figure 4 Levels of six predominant intestinal bacterial populations in healthy age- and sex-matched controls.
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that of the Enterobacteriaceae in most of the healthy
controls in this and our previous study [23]. Our previ-
ous research showed that the B/E ratio is useful for
monitoring microecological disruption in the intestine
during the progression of liver disease [23].
Secondary infections in most critically ill patients were
caused by exogenous rather than endogenous bacteria,
most of which were respiratory infections caused by
Candida species and multidrug-resistant A. baumannii
and K. pneumoniae. Previous in vitro and in vivo studies
have revealed that bacterial adherence to the surface of
cells in the respiratory tract is enhanced by influenza
virus infection, which contributes to the increased inci-
dence of secondary bacterial infection in influenza pa-
tients [27]. As a result, microecologically targeted
therapy was initiated to increase beneficial bacteria and
reduce the population of potential pathogens to enhance
resistance to intestinal colonization. Probiotics have
been proposed to have the potential to modulate host
innate immune responses outside the gastrointestinal
tract, including the respiratory mucosa [28,29]. Further-
more, probiotic prophylaxis of ventilator-associated
pneumonia wasreported to be successful [30]. The rela-
tive stability in the profiles of most patients under the
continual suppression by the same antibiotics suggested
that microbiota restoration therapy with probiotics
might help to maintain the relative stability of the mi-
crobial community during the period of antibiotic treat-
ment. We also observed that the effect of a combination
of antibiotics and pre- or pro-biotic intervention on the
predominant intestinal microbiome differed from that of
antibiotic or probiotic intervention alone. Individual risk
of infection is determined by the relationship between
an individual’s epidemiological exposure and net state of
immunosuppression. A weakened immune system in
elderly patients might account for the severity of
Figure 5 DGGE profiles of representative predominant intestinal bacteria from each group (A1, B1, E3, E8, C5, C6, and D6) and seven
healthy controls (NC1–NC7, age- and sex-matched with A1, B1, E3, E8, C5, C6, and D6, respectively). The approximate denaturant
concentrations in the gels were 37%, 57%, and 70%.
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influenza infection and serious complications [31]. How-
ever, prophylactic use of probiotics was ineffective in
elderly and critically ill patients in this study, and the
elderly were stillat particularly high risk for developing
secondary bacterial infection as a result of the primary
influenza and the complex antibiotic therapies. The arti-
ficial liver technology largely contributed to the failure
of pro- or pre-biotics to prevent respiratory infections in
these patients. Artificial liver technology was used to re-
move inflammatory cytokines induced by endotoxins be-
cause of the use of broad-spectrum antibiotics, which
was later confirmed to be a risk factor for critically ill
H7N9 patients. In any case, our data showed that
CBM588 failed to prevent respiratory infections in eld-
erly and critically ill patients, and its effect on increasing
levels of Bifidobacterium in the gut was unsatisfactory.
There is a clear need for large volunteer studies on ef-
fective prophylaxis strategies for secondary respiratory
infections in these elderly patients.
Results from this study demonstrated a transient stability
of the intestinal microbiota under continual suppression
with the same antibiotics in those patients treated with pro-
biotics. Perhaps the most interesting results in our study
were the different profiles of the intestinal microbiome that
were restored by C. butyricum, B. subtilis, and E. faecium
treatment. Bacillus subtilis- and E. faecium-coated capsules
seemed to promote an even distribution in the fecal micro-
biota, and contribute to restoration of the entire fecal
microbiota following antibiotic intervention. Microbiota
restoration strategies with multiple probiotics may be more
effective than single probiotics in restoring the entire intes-
tinal microbiome. Future studies using properly designed
clinical trials are required to support such claims and to un-
cover the mechanisms. Lactic acid bacteria also have pro-
tective effects against bacterial and viral infections in the
gastrointestinal and respiratory systems [32], and likely con-
tribute to the accelerated recovery of the innate immune re-
sponse [28]. The qPCR results in this study showed that
lactic acid bacteria recovered more quickly than the Bifido-
bacteria population, even under antibiotic suppression,
which might be beneficial to H7N9 patients.
Another aim of probiotic treatment is to ameliorate in-
flammation in these patients. All patients with influenza
virus H7N9 infection showed a sharp increase in inflam-
matory markers in the blood, caused by the primary and
secondary infections. There are many reports of anti-
inflammatory activity of probiotics, including CBM588
[10,33]. With regard to the assessment of microecologi-
cal treatment strategies, treatment of H7N9 infection
has previously focused on pathogenicity because of the
translocation and virulence of probiotics [34], and con-
flict between antibiotics that kill bacteria and microeco-
logical regulatory agents that promote bacterial growth,
so that the negative effects did not outweigh the bene-
fits. CRP is normally present in trace levels in the serum,
but increases rapidly in response to various infectious or
inflammatory conditions [35]. In this study, we found no
marked increase in CRP, and no cases of bacteremia and
pneumonia, caused by probiotics in the patients.
Prophylaxis against secondary infection with antibi-
otics and probiotics is as important as antiviral treat-
ment. It is necessary to integrate human and microbial
genomic data sets to analyze the risk of human disease
and achieve clinically effective strategies to maintain and
promote human health [36]. Prevention and treatment
of specific infections in these patients should be dictated
by knowledge of the infecting microorganism and its
sensitivity to antimicrobial agents, as well as the disrup-
tion of gut microflora balance during antibiotic
treatment. Future studies on the composition of the
dominant intestinal microbial populations in patients are
important for successful infection prevention. Unfortu-
nately, the number of patients in the present study was
small, and all had received antibiotics prior to being
transferred to our hospital. Well-designed animal trialsto
investigate the use of CBM588 as an adjunct to enhance
resistance to intestinal colonization are also needed.
Conclusions
Our results demonstrated a potential clinical strategy for
microbiota-targeted therapy in patients with influenza
virus H7N9 infection. The mortality of critically ill pa-
tients in our hospital was lower than in other parts of
China, which may be partly because of microbiota regu-
lation therapy to compensate for impaired intestinal
colonization resistance and to reduce bacteremia and
Figure 6 Principal components analysisfor all DGGE profiles of
patients. Colored dots show the fecal microbiome profiles of five
groups during follow-up. The plot is reoriented to maximize the
variation among lanes along the first three principal components
(contributions of 27.3, 13.8, and 10.8%, respectively) obtained from
BioNumerics software.
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sepsis. This study has noteworthy applications in the de-
velopment of personalized therapeutic strategies by real-
time monitoring of the predominant intestinal bacteria
using qPCR and DGGE, which is fast, cheap, and com-
paratively less laborious than high-throughput sequen-
cing technologies. Additionally, the present study is the
first to use intestinal B/E ratio for rapid nonintrusive as-
sessment of intestinal colonization resistance and
microbiota-regulated therapy in patients with influenza
virus H7N9 infection.
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